investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
The Biology of Perlecan in Cancer and Angiogenesis
Renato V Iozzo
2 Collaborator(s)
Funding source
National Cancer Institute (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Simon Barry
AstraZeneca (United Kingdom)
London, United Kingdom
Kurt Ballmer-Hofer
Paul Scherrer Institute
Zurich, Switzerland
Renato V Iozzo
Thomas Jefferson University
Philadelphia, United States
Related projects
Teresita Munoz-Antonia
Ponce School of Medicine – Moffitt Cancer Center Partnership
All cancers but non-melanoma skin cancer
Anne Goldfeld
Checkpoints of TNF Gene Regulation
All cancers but non-melanoma skin cancer
Peter J. Murray
(PQB2) Ontogeny of the tumor-immune interplay in a developmental malignancy
All cancers but non-melanoma skin cancer
George Q Daley
LIN28/let-7 MECHANISMS IN REPROGRAMMING AND METABOLISM
All cancers but non-melanoma skin cancer
Mark Udey
EpCAM (CD326) Function in Epithelial Cell Biology and Immunophysiology
All cancers but non-melanoma skin cancer
Hannah Wang
Understanding the HSF1 pathway and its potential for cancer therapy
All cancers but non-melanoma skin cancer
Dewi Harjanto
Does the RNA editor Apobec-1 shift microRNA targeting to a tumorigenic effect?
All cancers but non-melanoma skin cancer
Ira Pastan
Development of Improved Mesothelin Targeted Immunotoxins and other Tumor Specific Targeted Immunotoxins Using Proprietary Targeting Moieties
All cancers but non-melanoma skin cancer
Charles D Allis
Oncohistones: Role of Histone H3 Mutations in the Oncogenesis of Pediatric Cancers
All cancers but non-melanoma skin cancer
Pediatric oncology or childhood cancer